Thank you. Very nice article. The most interesting part is Buffet's quote "When a management team ..... it is the reputation of the business that remains intact.", which I found truly enlightening. This is right on the mark! For me, investing in SAND, is more about Nolan and his team than gold! I agree with you [and with Nolan for that matter] on the bearish sentiment for gold in the near term. However, longer term, with or without speculators, I see gold continuing to head higher. Thank you again..
You Can Bet On Gold Glittering Again [View article]
Dear David, Very good and well balanced article. Insightful analysis of what had occured leading to this bloodbath. The barrage of negative comments [on gold] above is just unbelievable and reflects the current sentiment! and could serve as a contrarian indicator!! I am like you, frustrated by the short term volatility, but continue to hold on to my positions (GLD, SLW, SAND, RGLD, FNV) built several years ago. I am well diversified and hence the overall effect on portfolio is tolerable. Keep up the nice work..
Sandstorm Should Over-Achieve In 2013 [View article]
Jason, when you do interview Nolan, please post a link or let me know if you have a personal website for us to see the interview. Going back to the all-time-high short position, is this a cause for concern for you? The large bets on further downside is worrisome to me. The other 2 gold streaming companies (FNV & RGLD) have seen uptick in short positions but the % of the increase is no where near the increase on SAND.
Sandstorm Should Over-Achieve In 2013 [View article]
Thank you for the insightful analysis. I thought that management's guidance for attributable production for 2013 was just too conservative! Your excellent analysis confirms this impression. However, in fairness to management they provided their guidance for 2013 before Luna updated their production guidance. On a separate note, are you alarmed at all by the huge spike recently in short interest to 3.3 million shares (all time high)? Thanks again..
To suggest any "target" price, you should have addressed basic valuation parameters. You did not look at multiples, NAV, or analyst targets! Absent such analysis, your article added no value to me.
Acacia Research Corporation - Meeting Unmet Needs [View article]
Very interesting article. Thank you very much. Buying ACTG anywhere between $20-$25 was indeed a great opportunity! I think that the Street had grown very frustrated with ACTG's overly-cautious disclosure practices. The press releases say very little and never quantify the effect of events (settlement/licensing/... In addition of course to the well-recognized lumpiness of revenue issue. I believe that the scarcity of information and inherent difficulty to analyze ACTG were among the reasons we were able to build positions at these levels! I like the business model a lot. I like the cash hoard. I like the growing patent portfolio. I see tremendous potential for ADAPTIX and ACCESS portfolios. All in all, it is a very exciting opportunity. Thanks again for a very nice article..
Why I'm 'In Cash' For Biotechs In A Bearish Market [View article]
Nice article. Thank you. Just one comment; assuming you are right that the market is heading south, do not you think that quality biotech plays are defensive by nature? Take a company like QCOR (which has its own unique issues), its revenue is unlikely to be affected by a recession. In fact, I tend to view quality (less risky) biotechs as smart holdings in times of uncertainty.
Questcor Pharmaceuticals - An Opportunity Following The Bear Raid? [View article]
Thank you very much for an objective analysis of QCOR situation. I find it really scary that shorts can actually orchestrate negative events for companies they short! Thanks again..
My Next Move With Sandstorm Gold [View article]
You Can Bet On Gold Glittering Again [View article]
Sandstorm Should Over-Achieve In 2013 [View article]
Sandstorm Should Over-Achieve In 2013 [View article]
Patience Is The Key With Sandstorm Gold [View article]
To suggest any "target" price, you should have addressed basic valuation parameters. You did not look at multiples, NAV, or analyst targets! Absent such analysis, your article added no value to me.
Acacia Research Corporation - Meeting Unmet Needs [View article]
Why I'm 'In Cash' For Biotechs In A Bearish Market [View article]
Questcor III: After The Earnings [View article]
Questcor Pharmaceuticals - An Opportunity Following The Bear Raid? [View article]
Citigroup Valuation Suggests A Reality Check With A Warning [View article]